InnoCare Pharma Ltd
SSE:688428
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
InnoCare Pharma Ltd
SSE:688428
|
CN |
|
U
|
Uni-President China Holdings Ltd
SWB:58U
|
CN |
|
T
|
Taekyung Chemical Co Ltd
KRX:006890
|
KR |
|
B
|
Beijing YanDong MicroElectronic Co Ltd
SSE:688172
|
CN |
|
OneMeta Inc
OTC:ONEI
|
US |
|
W
|
Wheeler Real Estate Investment Trust Inc
NASDAQ:WHLR
|
US |
|
S
|
SSE PLC
OTC:SSEZY
|
UK |
Cash Flow Statement
Cash Flow Statement
InnoCare Pharma Ltd
| Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | |||||||||
| Cash Taxes Paid |
14
|
(6)
|
(36)
|
(89)
|
(114)
|
(133)
|
(127)
|
(139)
|
|
| Change in Working Capital |
4
|
(204)
|
(349)
|
(633)
|
(652)
|
(624)
|
(627)
|
(672)
|
|
| Cash from Operating Activities |
70
N/A
|
(129)
N/A
|
(179)
-39%
|
(366)
-104%
|
(225)
+38%
|
(145)
+36%
|
(117)
+19%
|
84
N/A
|
|
| Investing Cash Flow | |||||||||
| Capital Expenditures |
17
|
(12)
|
(28)
|
(78)
|
(67)
|
(48)
|
(45)
|
(70)
|
|
| Other Items |
487
|
(104)
|
1 389
|
1 189
|
754
|
1 339
|
(524)
|
(177)
|
|
| Cash from Investing Activities |
505
N/A
|
(116)
N/A
|
1 361
N/A
|
1 111
-18%
|
687
-38%
|
1 291
+88%
|
(569)
N/A
|
(247)
+57%
|
|
| Financing Cash Flow | |||||||||
| Net Issuance of Common Stock |
1
|
8
|
18
|
18
|
18
|
27
|
19
|
19
|
|
| Net Issuance of Debt |
7
|
(17)
|
108
|
225
|
187
|
209
|
208
|
31
|
|
| Cash Paid for Dividends |
(0)
|
(1)
|
(355)
|
(363)
|
(371)
|
(379)
|
(33)
|
(33)
|
|
| Other |
(6)
|
(14)
|
(24)
|
(166)
|
(79)
|
(81)
|
(79)
|
36
|
|
| Cash from Financing Activities |
2
N/A
|
(24)
N/A
|
(253)
-974%
|
(286)
-13%
|
(245)
+14%
|
(225)
+8%
|
114
N/A
|
53
-54%
|
|
| Change in Cash | |||||||||
| Effect of Foreign Exchange Rates |
24
|
25
|
4
|
17
|
11
|
6
|
5
|
(63)
|
|
| Net Change in Cash |
600
N/A
|
(243)
N/A
|
933
N/A
|
477
-49%
|
227
-52%
|
928
+308%
|
(567)
N/A
|
(173)
+69%
|
|
| Free Cash Flow | |||||||||
| Free Cash Flow |
87
N/A
|
(141)
N/A
|
(207)
-47%
|
(444)
-114%
|
(292)
+34%
|
(193)
+34%
|
(162)
+16%
|
14
N/A
|
|